Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification - PubMed (original) (raw)
. 2006 Nov 1;24(31):5070-8.
doi: 10.1200/JCO.2006.06.1879.
Frank Berthold, Patrick Warnat, Barbara Hero, Yvonne Kahlert, Rüdiger Spitz, Karen Ernestus, Rainer König, Stefan Haas, Roland Eils, Manfred Schwab, Benedikt Brors, Frank Westermann, Matthias Fischer
Affiliations
- PMID: 17075126
- DOI: 10.1200/JCO.2006.06.1879
Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification
André Oberthuer et al. J Clin Oncol. 2006.
Abstract
Purpose: To develop a gene expression-based classifier for neuroblastoma patients that reliably predicts courses of the disease.
Patients and methods: Two hundred fifty-one neuroblastoma specimens were analyzed using a customized oligonucleotide microarray comprising 10,163 probes for transcripts with differential expression in clinical subgroups of the disease. Subsequently, the prediction analysis for microarrays (PAM) was applied to a first set of patients with maximally divergent clinical courses (n = 77). The classification accuracy was estimated by a complete 10-times-repeated 10-fold cross validation, and a 144-gene predictor was constructed from this set. This classifier's predictive power was evaluated in an independent second set (n = 174) by comparing results of the gene expression-based classification with those of risk stratification systems of current trials from Germany, Japan, and the United States.
Results: The first set of patients was accurately predicted by PAM (cross-validated accuracy, 99%). Within the second set, the PAM classifier significantly separated cohorts with distinct courses (3-year event-free survival [EFS] 0.86 +/- 0.03 [favorable; n = 115] v 0.52 +/- 0.07 [unfavorable; n = 59] and 3-year overall survival 0.99 +/- 0.01 v 0.84 +/- 0.05; both P < .0001) and separated risk groups of current neuroblastoma trials into subgroups with divergent outcome (NB2004: low-risk 3-year EFS 0.86 +/- 0.04 v 0.25 +/- 0.15, P < .0001; intermediate-risk 1.00 v 0.57 +/- 0.19, P = .018; high-risk 0.81 +/- 0.10 v 0.56 +/- 0.08, P = .06). In a multivariate Cox regression model, the PAM predictor classified patients of the second set more accurately than risk stratification of current trials from Germany, Japan, and the United States (P < .001; hazard ratio, 4.756 [95% CI, 2.544 to 8.893]).
Conclusion: Integration of gene expression-based class prediction of neuroblastoma patients may improve risk estimation of current neuroblastoma trials.
Similar articles
- Prognostic impact of gene expression-based classification for neuroblastoma.
Oberthuer A, Hero B, Berthold F, Juraeva D, Faldum A, Kahlert Y, Asgharzadeh S, Seeger R, Scaruffi P, Tonini GP, Janoueix-Lerosey I, Delattre O, Schleiermacher G, Vandesompele J, Vermeulen J, Speleman F, Noguera R, Piqueras M, Bénard J, Valent A, Avigad S, Yaniv I, Weber A, Christiansen H, Grundy RG, Schardt K, Schwab M, Eils R, Warnat P, Kaderali L, Simon T, Decarolis B, Theissen J, Westermann F, Brors B, Fischer M. Oberthuer A, et al. J Clin Oncol. 2010 Jul 20;28(21):3506-15. doi: 10.1200/JCO.2009.27.3367. Epub 2010 Jun 21. J Clin Oncol. 2010. PMID: 20567016 - Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature.
De Preter K, Vermeulen J, Brors B, Delattre O, Eggert A, Fischer M, Janoueix-Lerosey I, Lavarino C, Maris JM, Mora J, Nakagawara A, Oberthuer A, Ohira M, Schleiermacher G, Schramm A, Schulte JH, Wang Q, Westermann F, Speleman F, Vandesompele J. De Preter K, et al. Clin Cancer Res. 2010 Mar 1;16(5):1532-41. doi: 10.1158/1078-0432.CCR-09-2607. Epub 2010 Feb 23. Clin Cancer Res. 2010. PMID: 20179214 - Gene expression profiling of primary cutaneous melanoma and clinical outcome.
Winnepenninckx V, Lazar V, Michiels S, Dessen P, Stas M, Alonso SR, Avril MF, Ortiz Romero PL, Robert T, Balacescu O, Eggermont AM, Lenoir G, Sarasin A, Tursz T, van den Oord JJ, Spatz A; Melanoma Group of the European Organization for Research and Treatment of Cancer. Winnepenninckx V, et al. J Natl Cancer Inst. 2006 Apr 5;98(7):472-82. doi: 10.1093/jnci/djj103. J Natl Cancer Inst. 2006. PMID: 16595783 - Cross-study analysis of gene expression data for intermediate neuroblastoma identifies two biological subtypes.
Warnat P, Oberthuer A, Fischer M, Westermann F, Eils R, Brors B. Warnat P, et al. BMC Cancer. 2007 May 25;7:89. doi: 10.1186/1471-2407-7-89. BMC Cancer. 2007. PMID: 17531100 Free PMC article. Review. - Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome.
Ross JS. Ross JS. Adv Anat Pathol. 2009 Jul;16(4):204-15. doi: 10.1097/PAP.0b013e3181a9d4bf. Adv Anat Pathol. 2009. PMID: 19546609 Review.
Cited by
- Identification of MYCN non-amplified neuroblastoma subgroups points towards molecular signatures for precision prognosis and therapy stratification.
Hu X, Zhou Y, Hill C, Chen K, Cheng C, Liu X, Duan P, Gu Y, Wu Y, Ewing RM, Li Z, Wu Z, Wang Y. Hu X, et al. Br J Cancer. 2024 May;130(11):1841-1854. doi: 10.1038/s41416-024-02666-y. Epub 2024 Mar 29. Br J Cancer. 2024. PMID: 38553589 Free PMC article. - Target Genes of c-MYC and MYCN with Prognostic Power in Neuroblastoma Exhibit Different Expressions during Sympathoadrenal Development.
Yuan Y, Alzrigat M, Rodriguez-Garcia A, Wang X, Bexelius TS, Johnsen JI, Arsenian-Henriksson M, Liaño-Pons J, Bedoya-Reina OC. Yuan Y, et al. Cancers (Basel). 2023 Sep 16;15(18):4599. doi: 10.3390/cancers15184599. Cancers (Basel). 2023. PMID: 37760568 Free PMC article. - Development and validation of a 21-gene prognostic signature in neuroblastoma.
Gupta M, Kannappan S, Jain M, Douglass D, Shah R, Bose P, Narendran A. Gupta M, et al. Sci Rep. 2023 Aug 2;13(1):12526. doi: 10.1038/s41598-023-37714-9. Sci Rep. 2023. PMID: 37532697 Free PMC article. - Signature literature review reveals AHCY, DPYSL3, and NME1 as the most recurrent prognostic genes for neuroblastoma.
Chicco D, Sanavia T, Jurman G. Chicco D, et al. BioData Min. 2023 Mar 4;16(1):7. doi: 10.1186/s13040-023-00325-1. BioData Min. 2023. PMID: 36870971 Free PMC article. - A Simple, Test-Based Method to Control the Overestimation Bias in the Analysis of Potential Prognostic Tumour Markers.
Ognibene M, Pezzolo A, Cavanna R, Cangelosi D, Sorrentino S, Parodi S. Ognibene M, et al. Cancers (Basel). 2023 Feb 13;15(4):1188. doi: 10.3390/cancers15041188. Cancers (Basel). 2023. PMID: 36831529 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous